J&J's $1.3 Bil. Inverness Buy Would End Royalty-Based Relationship
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson's $1.3 bil. proposed acquisition of Inverness Medical Technology's diabetes care business builds on the firms' ongoing glucose meter and strip supply relationship begun in 1995.
You may also be interested in...
Animas IPO: Insulin Pump Maker Offers Up To $69 Mil. In Stock
Proceeds from Animas Corp.'s initial public offering will support sales and marketing of the IR 1200 third-generation insulin pump and evaluation of continuous glucose sensor technology licensed from Thomas Jefferson University, the manufacturer notes
Animas IPO: Insulin Pump Maker Offers Up To $69 Mil. In Stock
Proceeds from Animas Corp.'s initial public offering will support sales and marketing of the IR 1200 third-generation insulin pump and evaluation of continuous glucose sensor technology licensed from Thomas Jefferson University, the manufacturer notes
Lifescan Looks To InDuo Launch To Help Sustain 2001 Diabetes Care Growth
Johnson & Johnson's Lifescan unit is counting on this month's U.S. launch of the One Touch InDuo combination glucose monitoring and insulin dosing system to help sustain robust base operating growth following an 11% gain in the first half of 2001.